Cargando…
Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma
Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) are limited, especially for those with progressive disease and for those who experience treatment failure. Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has been approved for the treatment...
Autores principales: | Fonseca, Paula J., Uriol, Esther, Galván, José A., Álvarez, Carlos, Pérez, Quionia, Villanueva, Noemi, Berros, José P., Izquierdo, Marta, Viéitez, José M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764965/ https://www.ncbi.nlm.nih.gov/pubmed/24019785 http://dx.doi.org/10.1159/000354754 |
Ejemplares similares
-
A Case of Podocytic Infolding Glomerulopathy with Focal Segmental Glomerulosclerosis
por: Iguchi, Akira, et al.
Publicado: (2013) -
Familial Adenomatous Polyposis and Crohn's Disease in One Patient: Dilemmas and Concerns
por: Fidalgo, Catarina, et al.
Publicado: (2013) -
Diphenylcyclopropenone-Induced Vitiligo in a Patient with Alopecia Universalis
por: Riad, Hassan, et al.
Publicado: (2013) -
Signet-Ring Cutaneous Squamous Cell Carcinoma Arising on the Back of the Finger
por: Nakajima, Koji, et al.
Publicado: (2013) -
Subacute Cutaneous Lupus Erythematosus Triggered by Radiotherapy
por: Kolm, I., et al.
Publicado: (2013)